Publications by authors named "Rossignol P"
Aims: Early identification of healthy subjects prone to develop cardiac dysfunction may be instrumental to prevention strategies. Our study aimed to evaluate whether circulating levels of growth differentiation factor-15 (GDF-15) could predict adverse changes in echocardiographic indexes of cardiac structure and function in an initially healthy populational familial cohort with a long follow-up (STANISLAS cohort).
Methods And Results: We evaluated 1679 participants (49 ± 14 years, 48% males) included in the fourth visit (V4) of the STANISLAS cohort with available GDF-15 measurements (Olink proteomic analysis) and echocardiographic parameters.
Background: Ceramide and phosphatidylcholine lipids-based risk score (CERT2) has shown a strong prognostic value in predicting cardiovascular (CV) events in patients with ischemic heart disease. This study aimed to investigate the prognostic value of CERT2 risk score in patients with heart failure (HF).
Methods: The current study combines data for 4234 subjects from the COMMANDER-HF trial and 1227 subjects from the GISSI-HF trial, which enrolled patients with a history of HF.
Background: Bladder dysfunction entails overactive bladder (OAB) defined as symptoms of urinary urgency, frequency, and/or nocturia with or without incontinence if there is no obvious pathology or infection or lower urinary tract symptoms that includes recognized causes of bladder dysfunction.
Methods: Literature search.
Results: Symptoms of OAB are reported in about 15% of the adult US population.
Aims: Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart failure (HF). We explored the association between proteomic biomarkers and left ventricular hypertrophy (LVH), diastolic dysfunction (DD) and incident HF in three population-based cohorts.
Methods And Results: A chip was used to measure 92 protein biomarkers in blood samples from >1500 Malmö Preventive Project (MPP) participants, of whom 514 had LVH (34%), 462 had DD (32.
Article Synopsis
- Study investigates the use of patiromer, a potassium binder, to improve the effectiveness of RAAS inhibitors in patients with heart failure and hyperkalemia.
- In a trial with over 1,000 patients, those with hyperkalemia were able to optimize their medication while on patiromer, showing a slight reduction in serum potassium levels compared to placebo.
- Results suggest patiromer helps patients with current hyperkalemia maintain optimal doses of medication more effectively than those with a history of hyperkalemia, enhancing treatment outcomes for heart failure management.
Article Synopsis
- Hyperkalemia (HK) impacts the effectiveness of renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists (MRAs) in patients with heart failure with reduced ejection fraction (HFrEF).
- The study analyzed patients with HFrEF and either HK or a history of HK during a run-in phase designed to optimize their RAS inhibitor and MRA doses using patiromer.
- Results showed significant increases in the use of RAS inhibitors and MRAs among patients meeting the optimization criteria, indicating that patiromer helped enhance treatment for those with HK or a history of HK.
Article Synopsis
- The study investigated the effects of spironolactone on blood pressure (BP) during exercise in heart failure (HF) patients, finding that it significantly reduced both pre- and post-exercise BP levels over 9 months.
- While spironolactone showed a small improvement in the number of completed shuttles during exercise tests, there was no significant difference in overall exercise capacity or quality of life (QoL) between the spironolactone group and the control group.
- The results suggest that while spironolactone can lower BP in patients at increased risk of HF, it does not enhance their ability to exercise or improve their overall well-being.
Article Synopsis
- Impaired left ventricular-arterial coupling (VAC) is linked to worse outcomes in heart disease and heart failure (HF), and this study seeks to understand its relationship with specific proteins related to HF.
- Researchers examined data from 1,309 participants in the STANISLAS family cohort, analyzing how 32 HF-related proteins correlate with VAC measured through pulse wave velocity (PWV) and global longitudinal strain (GLS).
- Results showed that elevated levels of proteins like MMP-2 and NT-proBNP were associated with better VAC, suggesting that these proteins may play a role in the heart's compensatory mechanisms during cardiac stress.
Article Synopsis
- - The study evaluated the effectiveness of patiromer, a drug used to manage high potassium levels (hyperkalemia), in patients with heart failure and chronic kidney disease, especially focusing on its benefits when used alongside RAAS inhibitors.
- - Results showed that patiromer was particularly effective in controlling serum potassium levels in patients with more advanced chronic kidney disease (CKD), without increasing the risk of adverse effects.
- - The research concluded that patiromer allows for safer use of RAAS inhibitors in patients with heart failure, especially those with lower estimated glomerular filtration rates (eGFR), while minimizing hyperkalemia risk.
Article Synopsis
- The study aims to identify biomarkers linked to new-onset kidney function decline in initially healthy individuals, ultimately improving patient management.
- It analyzed data from 1,087 participants over a 20-year period, focusing on the relationship between proteins and gene expressions and changes in glomerular filtration rate (GFR).
- Key findings included several proteins and genes associated with kidney dysfunction, highlighting the roles of extracellular matrix, cardiovascular remodeling, and inflammation in early GFR decline and suggesting potential avenues for future research in biomarkers and treatments.
Aims: Few randomized trials assessed the changes over time in the chronotropic heart rate (HR) reactivity (CHR), HR recovery (HRR) and exercise endurance (EE) in response to the incremental shuttle walk test (ISWT). We addressed this issue by analysing the open HOMAGE (Heart OMics in Aging) trial.
Methods: In HOMAGE, 527 patients prone to heart failure were randomized to usual treatment with or without spironolactone (25-50 mg/day).
Background And Hypothesis: Heart failure is characterized as cardiac dysfunction resulting in elevated cardiac filling pressures with symptoms and signs of congestion. Distinguishing heart failure from other causes of similar presentations in patients with kidney failure is challenging but necessary, and is needed in randomized controlled trials (RCTs) to accurately estimate treatment effects. The objective of this study was to review heart failure events, their diagnostic criteria and adjudication in RCTs of patients with kidney failure treated with dialysis.
View Article and Find Full Text PDFArticle Synopsis
- Statins are commonly prescribed to lower cardiovascular disease risk but showed limited effectiveness for patients with end-stage renal disease on hemodialysis in large studies.
- Researchers examined the gene expression changes in kidney cells due to statin treatment and identified specific biomarkers linked to these changes.
- Four patient clusters were formed based on these biomarkers, highlighting that certain clusters, particularly those with specific levels of interleukin 6 and hepatocyte growth factor, were associated with an increased risk of serious cardiovascular events.
Objective: Heart failure (HF) is characterised by collagen deposition. Urinary proteomic profiling (UPP) followed by peptide sequencing identifies parental proteins, for over 70% derived from collagens. This study aimed to refine understanding of the antifibrotic action of spironolactone.
View Article and Find Full Text PDFBackground And Aims: Chronic inflammation plays a key role in arterial stiffness pathogenesis. Dietary components can display anti- or pro-inflammatory properties. Nonetheless, the association between the diet's overall inflammatory potential and arterial stiffness is unclear.
View Article and Find Full Text PDFAims: High left ventricular filling pressure increases left atrial volume and causes myocardial fibrosis, which may decrease with spironolactone. We studied clinical and proteomic characteristics associated with left atrial volume indexed by body surface area (LAVi), and whether LAVi influences the response to spironolactone on biomarker expression and clinical variables.
Methods And Results: In the HOMAGE trial, where people at risk of heart failure were randomized to spironolactone or control, we analysed 421 participants with available LAVi and 276 proteomic measurements (Olink) at baseline, month 1 and 9 (mean age 73 ± 6 years; women 26%; LAVi 32 ± 9 ml/m).
Acute kidney injury (AKI) often complicates sepsis and is associated with high morbidity and mortality. In recent years, several important clinical trials have improved our understanding of sepsis-associated AKI (SA-AKI) and impacted clinical care. Advances in sub-phenotyping of sepsis and AKI and clinical trial design offer unprecedented opportunities to fill gaps in knowledge and generate better evidence for improving the outcome of critically ill patients with SA-AKI.
View Article and Find Full Text PDFBackground: Many outcomes of high priority to patients and clinicians are infrequently and inconsistently reported across trials in chronic kidney disease (CKD), which generates research waste and limits evidence-informed decision making. We aimed to generate consensus among patients/caregivers and health professionals on critically important outcomes for trials in CKD prior to kidney failure and the need for kidney replacement therapy, and to describe the reasons for their choices.
Methods: This was an online two-round international Delphi survey.
Significance Statement: This large observational cohort study aimed to investigate the relationship between dialysate and plasma sodium concentrations and mortality among maintenance hemodialysis patients. Using a large multinational cohort of 68,196 patients, we found that lower dialysate sodium concentrations (≤138 mmol/L) were independently associated with higher mortality compared with higher dialysate sodium concentrations (>138 mmol/L). The risk of death was lower among patients exposed to higher dialysate sodium concentrations, regardless of plasma sodium levels.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the clinical and proteomic profiles of patients at risk for heart failure, distinguishing between those with and without coronary artery disease (CAD) or prior myocardial infarction (MI).
- It involved 527 participants and identified distinct protein markers associated with CAD and MI, revealing higher levels of certain proteins like MMP-7 in those with CAD or MI.
- The use of spironolactone in participants led to changes in these protein levels over 9 months, suggesting that treatment may influence specific biomarkers related to heart failure risk.
Chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) represents a major public health issue; it develops in about 30%-40% of patients with diabetes mellitus and is the most common cause of CKD worldwide. Patients with CKD and T2D are at high risk of both developing kidney failure and of cardiovascular events. Renin-angiotensin system (RAS) blockers were considered the cornerstone of treatment of albuminuric CKD in T2D for more than 20 years.
View Article and Find Full Text PDF